Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15302654 | 1.00 | PIK3CG (0.37) | PIK3CGDHODHADORA2AMAPK14PIK3CD | |
| SCHEMBL9953062 | 1.00 | PIK3CG (0.37) | PIK3CGDHODHADORA2AMAPK14PIK3CD | |
| SCHEMBL20061319 | 0.83 | PIK3CG (0.47) | PIK3CGPIK3CD | |
| SCHEMBL20081337 | 0.83 | PIK3CG (0.47) | PIK3CGPIK3CD | |
| SCHEMBL20068031 | 0.83 | PIK3CG (0.47) | PIK3CGPIK3CD | |
| SCHEMBL28561171 | 0.83 | PIK3CG (0.47) | PIK3CGPIK3CD | |
| SCHEMBL9223901 | 0.77 | DHODH (0.42) | PIK3CGDHODHMAPK14METSLC40A1 | |
| SCHEMBL9959092 | 0.75 | DHODH (0.40) | PIK3CGDHODHADORA2AMAPK14MET | |
| SCHEMBL9953063 | 0.74 | DHODH (0.33) | DHODHPIK3CD | |
| SCHEMBL9959766 | 0.74 | DHODH (0.35) | DHODHADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| WO-2012087784-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CG 59/4885DHODH 2700/4885ADORA2A 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.